Alzheimer’s Disease Group
If you have questions concerning the projects this workgroup is undertaking, please contact the work group chair(s).
If you have questions concerning this web page or our social media accounts, and/or you have resources that you would like to share with the public, please contact the work group outreach liaison(s).
Link to Data Access Portal
The Alzheimer’s disease Working Group (PGC-ALZ) is a relatively young group that was initiated in 2016 by Danielle Posthuma and Ole Andreassen. This collaborative effort shares the main ambition to identify novel genetic risk factors for Alzheimer’s disease to contribute to better understanding of the underlying disease pathology that is required for the development of improved treatment in the future. After the first two years of intensive data collection, by gathering public genetic data and launching new collaborations, the first GWAS paper was published early 2019 (PMID 30617256).
The current goals are to:
– Discover novel genetic risk factors and identify potential drug targets
– Work closely with scientist that functionally follow up well defined risk loci
– Characterize the genetic architecture, such as genetic heterogeneity
– Work closely with clinicians to translate the findings to clinical setting for precision medicine application (polygenic risk prediction tools)
– Increase our knowledge about trans-ancestry genetic risk factors – beyond Europeans
– Facilitate the collaboration between international genetics Alzheimer’s disease consortia
– Constantly increase the number of participants to improve power
The PGC-ALZ members stay connected and updated with regular conference calls. If you are also interested in becoming a PGC-ALZ member, we welcome your participation and are eager to collaborate with investigators who might be willing to share raw genotypic data or effect sizes. If you are interested in learning more about our group, please contact Iris Jansen.
Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, … Posthuma D (2019). Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nature Genetics, 51, 404-413. https://www-nature-com.vu-nl.idm.oclc.org/articles/s41588-018-0311-9%C2%A0
Drange OK, Smeland OB, Shadrin AA, Finseth PI, Witoelar A, Frei O (2019). Genetic overlap between Alzheimer’s disease and bipolar disorder implicates the MARK2 and VAC14 genes. Frontiers in Neuroscience doi: https://doi.org/10.3389/fnins.2019.00220
Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Rongve A, … Posthuma D (2020). Largest GWAS (N=1,126,563) of Alzheimer’s Disease Implicates Microglia and Immune Cells. MedRxiv doi: https://doi.org/10.1101/2020.11.20.20235275